Charles River Laboratories
CRL
627 hedge funds and large institutions have $10.8B invested in Charles River Laboratories in 2022 Q4 according to their latest regulatory filings, with 106 funds opening new positions, 224 increasing their positions, 220 reducing their positions, and 54 closing their positions.
96% more first-time investments, than exits
New positions opened: 106 | Existing positions closed: 54
9% more capital invested
Capital invested by funds: $9.9B → $10.8B (+$869M)
8% more funds holding
Funds holding: 583 → 627 (+44)
2% more repeat investments, than reductions
Existing positions increased: 224 | Existing positions reduced: 220
1.22% less ownership
Funds ownership: 98.95% → 97.73% (-1.2%)
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
54% less call options, than puts
Call options by funds: $20M | Put options by funds: $43M
Top Buyers
| 1 |
Millennium Management
New York
|
+$95.6M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$69.7M |
| 3 |
TGA
TPG GP A
Fort Worth,
Texas
|
+$66M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$65.5M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$58.1M |
Top Sellers
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$98.4M |
| 2 |
SCA
Southpoint Capital Advisors
New York
|
-$98.4M |
| 3 |
BlackRock
New York
|
-$76.6M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$65.6M |
| 5 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$53.2M |
CRL Hedge Fund Activity: Q4 2022 in Review
627 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q4 2022, worth a combined $10.8B — up 8.8% from $9.9B a quarter earlier.
Buyers outnumbered sellers: 106 funds opened new CRL positions and 54 closed out — a net gain of 52 holders — while 224 added to existing stakes and 220 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $95.6M. The largest seller was Camber Capital Management, exiting entirely with an estimated $98.4M sold.
- 627 institutional investors held Charles River Laboratories (CRL) as of Q4 2022, up from 583 in Q3 2022.
- Funds reported $10.8B of Charles River Laboratories stock for Q4 2022, up 8.8% quarter-over-quarter.
- 106 funds opened new Charles River Laboratories positions in Q4 2022 and 54 closed out, a net change of +52 holders.
- The largest Charles River Laboratories buyer in Q4 2022 was Millennium Management, an estimated $95.6M added.
- The largest Charles River Laboratories seller in Q4 2022 was Camber Capital Management, an estimated $98.4M sold.
Based on aggregated 13F filings for Q4 2022.